Drug Trial Radar · NCT03654105
Screening and Multiple Intervention on Lung Epidemics
Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2,000
Planned (sponsor's estimate)
Start
Jul 23, 2019
Primary completion
Dec 31, 2024
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Istituto Di Ricerche Farmacologiche Mario Negri
- First posted
- Aug 31, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 55 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This prospective randomized pilot trial will evaluate a multiple intervention program of prevention in lifelong smokers aiming at reduction of chronic inflammation status through treatment with low-dose acetylsalicylic acid (ASA), smoking cessation with cytisine, targeted modification of diet and physical activity, in addition to early diagnosis with annual ultra low-dose spiral computed tomography (LDCT).
Conditions
- Inflammation
- Smoking Cessation
- Diet Modification
- Physical Activity
- Lung Cancer
Interventions
CytisineDrug
Cytisine administration will be randomized 1:1 in standard (40 days)and prolonged treatment (84 days). Subjects will be educated on how to take the product and informed about possible adverse effects.
Acetylsalicylic acidDrug
The treatment will consist of Acetylsalicylic acid at 100mg once a day
Diet Modification and Physical Activity IncreaseOther
It will be proposed: 1. an optimal diet with the aim of favoring control of weight, abdominal fat and adequate nutritional status without increasing the levels of IGF-I and inflammatory factors or glycemic peaks, with periodic verification of the results 2. a regular and sustainable physical activity program with periodic verification of the results.
early lung cancer detectionDiagnostic test
standard treatment for early lung cancer detection with ultra low dose CT
spirometry with CO testDiagnostic test
spirometry with CO test
anthropometic data collectionOther
anthropometic data collection
blood testOther
blood test to assess the metabolic and inflammatory profile
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in chronic inflammatory statusTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.